MetaCap

Abivax SA ADR (ABVX)

NASDAQ: ABVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

73.20-7.45 (-9.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABVX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$6.08
52-week range
62.70 – 148.83
Day range
62.97 – 79.74
Volume / Avg
14.85M / 1.35M
Beta
—
Next earnings
Dec 21, 2026

52-week range

$62.70$148.83

ABVX stock today

Abivax SA (ABVX) closed at $73.20 on Nov 20, down 9.24% (-$7.45), versus the S&P 500's 3.70% decline. Volume was 11.0x the average at 14.85M shares, a sign of unusually heavy trading. Shares are 50.8% below their 52-week high of $148.83, set on Dec 24, 2025 and 16.7% above the 52-week low of $62.70, near the bottom of the past year's range.

ABVX is down 45.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.5%. Abivax SA has posted a net loss over the last twelve months (EPS of -$6.08), so its P/E ratio is not meaningful. Abivax SA's next earnings report is expected on Dec 21, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Abivax SA

Company profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Marc M. P. de Garidel M.B.A.
Headquarters
Paris
Employees
98
IPO year
2023
Website
abivax.com

Analyst forecast

Forecast

Consensus (12 analysts)

none

Avg. price target

$163.58+123.47%

  • Strong buy 4
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $142.00High $181.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 21, 2026
EPS estimate
$-1.27

ABVX news

All ABVX news

Abivax SA peers

Health Care sector
ABVX peer companies
CompanyPrice% ChgMarket capCompare
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs ABVX
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs ABVX
SUPNSupernus Inc.28.61+0.92%$5.94Bvs ABVX
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs ABVX
ARWRArrowhead Pharmaceuticals Inc.41.37-5.22%$5.85Bvs ABVX
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs ABVX
LGNDLigand Pharmaceuticals Incorporated286.85-0.03%$5.74Bvs ABVX
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs ABVX

Indexes, lists and sector

Abivax SA stock FAQ

What is Abivax SA's stock price today?

ABVX last traded at $73.20 as of Nov 20, 4:00 PM EST, down 9.24% on the day. Prices are delayed at least 15 minutes.

When is Abivax SA's next earnings date?

Abivax SA is expected to report earnings on Monday, December 21, 2026. Analysts expect EPS of $-1.27.

Who is Abivax SA's CEO?

Mr. Marc M. P. de Garidel M.B.A. is the chief executive officer of Abivax SA ADR, which has about 98 employees.

What is the ABVX 52-week high?

The 52-week high for ABVX is $148.83 and the 52-week low is $62.70. The stock is currently 50.8% below its high.

Compare ABVX